faa glp 1 What You Need to Know About GLP-1 Drugs What Are GLP-1 Agonists For

Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

How PlexusDx Supports a More Personalized Approach PlexusDx Precision Peptide Genetic Test may help provide context about your genetic predispositions in GLP-1 receptor signaling, appetite regulation, and metabolic response

however, the incidence was 14.5 per 100,000 person-years, and the increased risk attributable to semaglutide was modest

More serious but uncommon risks include pancreatitis, gallbladder disease, kidney issues, and thyroid tumors

One key difference lies in how it feels

Monitor critical pancreatic health